10-K/A: Chemed Corporation Amends 2024 Annual Report to Correct Equity Compensation Plan Information

Chemed Corporation files an amendment to its 2024 annual report to correct the number of securities available for future issuance under equity compensation plans.

Summary

• Chemed Corporation is filing an amendment (Amendment No. 1) to its Annual Report on Form 10-K for the year ended December 31, 2024.
• The amendment corrects the number of securities remaining available for future issuance under the equity compensation plans.
• The original 2024 Form 10-K was filed with the SEC on February 28, 2025.
• The amendment includes updated certifications from the company's principal executive officer and principal financial officer.
• The amendment does not modify or update any other information in the original 2024 Form 10-K or reflect events occurring after the original filing date.
• As of December 31, 2024, there were 1,235,051 stock options and performance share units outstanding under the company's equity compensation plans.
• The weighted average exercise price of outstanding options was $487.07.
• There were 435,455 securities remaining available for future issuance under equity compensation plans.
• This amount includes 52,870 shares allocated to certain employees which vest upon attainment of specified earnings per share targets and specified total shareholder return targets.

Sentiment

Score: 7

Explanation: The document is a routine amendment to correct a minor error, indicating standard corporate governance practices. The sentiment is neutral to slightly positive.

Positives

• The company is proactively correcting an error in its previously filed annual report.
• Updated certifications from the CEO and CFO are included.

Management Comments

• Kevin J. McNamara, President and Chief Executive Officer, and Michael D. Witzeman, Vice President, Chief Financial Officer, and Controller, certified the accuracy of the amended report.

Stakeholder Impact

• The correction of the equity compensation plan information ensures transparency for shareholders.
• The amendment provides accurate information to investors.

Key Dates

Keywords

equity compensation, amendment, Form 10-K, securities, Chemed Corporation, annual report